Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Paul A who wrote (2307)	10/30/1998 6:18:00 PM
From: jopawa	Read Replies (1) \| Respond to of 4676

Paul A, With all due respect, it's kind of silly to take a position and then set a stop loss 1/4 pt below the close. I hope the market maker opens it up on Monday at 9 3/8 just to take you out! John

To: Paul A who wrote (2307)	10/30/1998 8:40:00 PM
From: emil	Read Replies (1) \| Respond to of 4676

I started to have the same concerns, along with curiosity as to why there has not been a formal announcement regarding IBIS. I emailed Jane Greene. The next morning, I received a response. My follow up questions were responded to in the same day. I was impressed by her promptness. The following are the details: . As an ISIS shareholder, I am wondering why the IBIS division information was not formally announced in a news release? . . Dear Emil: The Ibis division is still somewhat in a formative stage as a research program. We will determine the appropriate time to formally introduce it. It is a program that has evolved to a large extent from our combinational program, so while the effort is innovative, is it a continuation of research efforts that have been underway for awhile. Best regards, Jane Green . . Then I replied this morning with a concern about the struggling stock price in light of others advancing, as well as timeframes for future news releases. The following is the response, which I received in the same day. . . Hello Emil: I wish I could give you a good explanation for why our stock behaved differently than many other biotech companies this week, but I cannot. We have not issued any negative news, and projects are progressing. It would be inappropriate to signal ahead of time when we are going to release news, so I cannot respond to that request. Our hope is that in a reasonable time, the market will recognize Isis' value. Our focus right now is on continuing to create value by advancing our clinical development programs and by continuing to strengthen the technological foundation of the company. Best regards, Jane Green . Comments?